Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cassava Sciences Inc SAVA

Healthcare
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on neuroscience. The Company's science is based on stabilizing, but not removing, a critical protein in the Alzheimer’s brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation. It has two biopharmaceutical assets under... see more

Recent & Breaking News (NDAQ:SAVA)

Cassava Sciences Invited by the NIH to Participate in Sachs 4th Annual Neuroscience Innovation Forum

GlobeNewswire April 26, 2021

Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release

GlobeNewswire April 21, 2021

Cassava Sciences Announces Full-year 2020 Financial Results and Business Highlights

GlobeNewswire March 23, 2021

Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam

GlobeNewswire March 9, 2021

Cassava Sciences to Present at the H.C. Wainwright Global Life Sciences Conference

GlobeNewswire March 8, 2021

Cassava Sciences to Present at SVB Leerink Global Healthcare Conference

GlobeNewswire February 23, 2021

Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer's Disease

GlobeNewswire February 22, 2021

Cassava Sciences Announces Closing of $200 Million Registered Direct Offering

GlobeNewswire February 12, 2021

Cassava Sciences Announces $200 Million Registered Direct Offering of Common Stock

GlobeNewswire February 10, 2021

Cassava Sciences Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Clinical Program in Alzheimer's Disease

GlobeNewswire February 8, 2021

Cassava Sciences' Simufilam Improves Cognition and Behavior in Alzheimer's Disease in Interim Analysis of Open-label Study

GlobeNewswire February 2, 2021

Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer

GlobeNewswire January 4, 2021

USAN Modifies Lead Drug Candidate's Chemical Name to 'Simufilam'

GlobeNewswire November 27, 2020

Cassava Sciences Announces Pricing of $75 Million Public Offering of Common Stock

GlobeNewswire November 13, 2020

Cassava Sciences Announces Proposed Public Offering of Common Stock

GlobeNewswire November 12, 2020

Cassava Sciences Reports Third Quarter 2020 Financial Results

GlobeNewswire November 9, 2020

Cassava Sciences Announces Additional Clinical Data from a Phase 2b Study of Sumifilam in Alzheimer's Disease

GlobeNewswire November 4, 2020

Cassava Sciences' Phase 2b Clinical Results in Alzheimer's Selected as Late-Breaking News at CTAD 2020

GlobeNewswire September 30, 2020

Cassava Sciences Announces Final Results of a Phase 2b Clinical Study of Sumifilam in Patients with Alzheimer's Disease

GlobeNewswire September 14, 2020

Cassava Sciences to Hold Conference Call on Monday, September 14, 2020 at 8:30 am ET

GlobeNewswire September 11, 2020